1095 completed, 326 terminated, 170 recruiting, 140 active not recruiting. 920 Phase 2, 793 Phase 1, 176 Phase 3, 110 Not applicable, 16 Early Phase 1.
Follow Leukemia, Lymphocytic, Chronic, B-Cell: new trials by email Literature Review of Leukemia, Lymphocytic, Chronic, B-Cell trials Research Report on Leukemia, Lymphocytic, Chronic, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 44 | 2027-08-04 | 2026-09-10 |
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Tacabrutideg, Sonrotoclax, Obinutuzumab - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 30 | 2027-01-01 | 2026-10-21 |
| A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia Zanubrutinib, Obinutuzumab, Sonrotoclax - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2026-12-31 | 2026-06-30 |
| Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations Ibrutinib Oral Tablet, Venetoclax Oral Tablet, Epcoritamab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 44 | 2026-12-31 | 2026-07-31 |
| Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 35 | 2026-12-19 | 2026-05-12 |
| variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway Chronic Lymphocytic Leukemia, Haematological Malignancy | Not yet recruiting | The Royal Wolverhampton Hospitals NHS Trust | 130 | 2026-12-01 | 2026-09-15 | |
| Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Zanubrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 95 | 2026-12-01 | 2026-09-14 |
| RPM Signals in Outpatient CAR T Therapy Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome | Not yet recruiting | Current Health | 125 | 2026-12-01 | 2026-10-20 | |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 32 | 2026-11-15 | 2026-10-02 |
| Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Jennifer Woyach | 25 | 2026-11-01 | 2026-10-15 |
| Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies Chronic Lymphocytic Leukemia (CLL), Splenic Marginal Zone Lymphoma | Not yet recruiting | IRCCS San Raffaele | 64 | 2026-11-01 | 2026-08-13 | |
| Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor Nemtabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | Phase 2 | Not yet recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 32 | 2026-10-26 | 2026-10-21 |
| Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Nemtabrutinib, Lisocabtagene Maraleucel - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2026-10-15 | 2026-09-11 |
| A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) MK-1045, Acetaminophen (or similar antipyretic), Diphenhydramine (or similar antihistamine) - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 60 | 2026-10-09 | 2026-10-08 |
| Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI Epcoritamab - CLL, CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | University of California, Irvine | 24 | 2026-10-01 | 2026-09-14 |
| Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Nemtabrutinib, Venetoclax, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 30 | 2026-10-01 | 2026-07-08 |
| Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Kerry Rogers | 155 | 2026-10-01 | 2026-08-31 |
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | CSL Behring | 63 | 2026-09-15 | 2026-10-14 |
| Targeting IRAK4 in Chronic Lymphocytic Leukemia Peripheral blood sample collection - Chronic Lymphocytic Leukemia (CLL) | Not yet recruiting | IRCCS San Raffaele | 50 | 2026-09-01 | 2026-08-04 |
Showing 20 of 2018. Sign in to see all of them.
Lymphoma, Non-Hodgkin (745) · Lymphoma, Follicular (698) · Lymphoma, Mantle-Cell (668) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (632) · Lymphoma, B-Cell, Marginal Zone (628) · Lymphoma, Large B-Cell, Diffuse (595) · Lymphoma (524) · Leukemia (513) · Burkitt Lymphoma (464) · Hodgkin Disease (463) · Lymphoma, Large-Cell, Immunoblastic (418) · Leukemia, Myeloid, Acute (406) · Multiple Myeloma (393) · Waldenstrom Macroglobulinemia (344)
Chronic Disease (2018) · Disease Attributes (2018) · Hemic and Lymphatic Diseases (2018) · Pathologic Processes (2018) · Pathological Conditions, Signs and Symptoms (2018) · Immunoproliferative Disorders (2013) · Neoplasms by Histologic Type (2013) · Lymphatic Diseases (2010) · Immune System Diseases (2008) · Hematologic Diseases (1997) · Leukemia, Lymphoid (1989) · Lymphoproliferative Disorders (1971) · Leukemia, B-Cell (1956) · Neoplasms (1884) · Leukemia (1505)
Rituximab (315) · Cyclophosphamide (286) · fludarabine phosphate (213) · fludarabine (140) · ibrutinib (123) · Peripheral Blood Stem Cell Transplantation (116) · venetoclax (112) · Mycophenolic Acid (102) · obinutuzumab (94) · Lenalidomide (89) · Bendamustine Hydrochloride (88) · Whole-Body Irradiation (85) · Filgrastim (84) · Cyclosporine (78) · Tacrolimus (78)
National Cancer Institute (NCI) (134) · M.D. Anderson Cancer Center (117) · Fred Hutchinson Cancer Center (82) · Mayo Clinic (45) · Memorial Sloan Kettering Cancer Center (39) · City of Hope Medical Center (38) · Hoffmann-La Roche (36) · Gilead Sciences (34) · AbbVie (32) · Masonic Cancer Center, University of Minnesota (30) · National Heart, Lung, and Blood Institute (NHLBI) (30) · German CLL Study Group (25) · Case Comprehensive Cancer Center (24) · Roswell Park Cancer Institute (23) · Alliance for Clinical Trials in Oncology (21)
United States (1491) · Italy (166) · France (165) · Germany (142) · United Kingdom (136) · Spain (128) · Canada (124) · Australia (111) · China (108) · Poland (101) · Belgium (74) · Israel (70) · Austria (64) · Czechia (59) · South Korea (53)
Brenda Sandmaier (11) · Michael Hallek, MD (9) · Alessandra Ferrajoli, MD (8) · David Maloney (8) · Michael Choi, MD (7)
PMID 32499241, PMID 34515338, PMID 34398557, PMID 38620092, PMID 23524640, PMID 23065508, PMID 29358183, PMID 31196847, PMID 26182309, PMID 31023700, PMID 34608724, PMID 34865212, PMID 40266025, PMID 24615776, PMID 24615777, PMID 25103870, PMID 28751558, PMID 33131249, PMID 35829925, PMID 36442911, PMID 38502198, PMID 39563886, PMID 40396505, PMID 41843779, PMID 16344317, PMID 19238148, PMID 19826119, PMID 19949018, PMID 20028764, PMID 20882050, PMID 21816833, PMID 22002018, PMID 22133778, PMID 22289993, PMID 23547837, PMID 23886836, PMID 24450857, PMID 24450858, PMID 24615778, PMID 24782509, PMID 24797299, PMID 24916506, PMID 24990615, PMID 26472751, PMID 26813675, PMID 27482888, PMID 27503501, PMID 27601462, PMID 28714866, PMID 29255066
P30CA015704 (35), P30CA015083 (26), P30CA033572 (26), 2023 (16), P30CA043703 (16), U10CA031946 (16), P30CA006973 (15), U01CA076576 (15), 2015 (14), P30CA016672 (14), P01CA018029 (12), P30CA016058 (12), P30CA022453 (12), 2009 (10), 2014 (10)